Back to Journals » Therapeutics and Clinical Risk Management » Volume 5

Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection

Authors Dalal P, Grafals M, Chhabra D, Gallon L

Published 13 January 2009 Volume 2009:5 Pages 139—149

DOI https://doi.org/10.2147/TCRM.S3068

Review by Single anonymous peer review

Peer reviewer comments 4



Pranav Dalal1, Monica Grafals2, Darshika Chhabra2, Lorenzo Gallon2

1Department of Medicine, Mount Sinai Hospital, Chicago, USA; 2Northwestern University–Feinberg School of Medicine, Chicago, USA

Abstract: Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is an inhibitor of inosine monophosphate dehydrogenase (IMPDH). It preferentially inhibits denovo pathway of guanosine nucleotide synthesis in T and B-lymphocytes and prevents their proliferation, thereby suppresses both cell mediated and humoral immune responses. Clinical trials in kidney transplant recipients have shown the efficacy of MMF in reducing the incidence and severity of acute rejection episodes. It also improves long term graft function as well as graft and patient survival in kidney transplant recipients. MMF is useful as a component of toxicity sparing regimens to reduce or avoid exposure of steroids or calcineurin inhibitor (CNI). Enteric-coated mycophenolate sodium (EC-MPS) can be used as an alternative immunosuppressive agent in kidney transplant recipients with efficacy and safety profile similar to MMF.

Keywords: mycophenolate mofetil, kidney transplantation, acute rejection, toxicity sparing

Creative Commons License © 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.